Welcome to Paid Research Studies




  • Conditions:   B-cell Acute Lymphoblastic Leukemia;   Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis;   Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
    Interventions:   Drug: ABL001;   Drug: Dasatinib;   Drug: Prednisone
    Sponsors:   Marlise R. Luskin;   Novartis
    Recruiting

  • Conditions:   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
    Interventions:   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Glioma;   High Grade Glioma;   Pontine Tumors
    Interventions:   Drug: Dasatinib;   Drug: Everolimus
    Sponsor:   University of Michigan Rogel Cancer Center
    Recruiting

  • Conditions:   Chronic Myelogenous Leukemia, Ph1-Positive;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: BP1001 (varying dose);   Drug: BP1001 (fixed dose);   Drug: Dasatinib
    Sponsor:   Bio-Path Holdings, Inc.
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Brain Neoplasm;   Recurrent Malignant Solid Neoplasm;   Refractory Brain Neoplasm
    Interventions:   Drug: Cyclophosphamide;   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Temsirolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Minimal Residual Disease
    Interventions:   Drug: Dasatinib;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Biological: Pembrolizumab
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Rhabdomyosarcoma;   Rhabdomyosarcoma- Alveolar;   Rhabdomyosarcoma-Embryonal
    Interventions:   Drug: Dasatinib;   Drug: Ganitumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Alzheimer Disease
    Intervention:   Drug: Dasatinib + Quercetin
    Sponsors:   The University of Texas Health Science Center at San Antonio;   Mayo Clinic
    Not yet recruiting

  • Conditions:   CML, Chronic Phase;   CML (Chronic Myelogenous Leukemia;   CML - Philadelphia Chromosome;   Chronic Myeloid Leukemia;   Chronic Myeloid Leukemia, Chronic Phase
    Interventions:   Drug: Bosutinib;   Drug: Dasatinib;   Drug: Imatinib;   Drug: Nilotinib
    Sponsor:   UNC Lineberger Comprehensive Cancer Center
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia, in Relapse;   Acute Lymphoblastic Leukemia With Failed Remission
    Interventions:   Drug: Palbociclib Oral Capsule;   Drug: Intrathecal Triple Therapy Given IT;   Drug: Dexamethasone;   Drug: Bortezomib;   Drug: Dasatinib;   Drug: Doxorubicin
    Sponsors:   St. Jude Children's Research Hospital;   Pfizer
    Recruiting

  • Conditions:   Breast Cancer;   Prostate Cancer;   Pancreatic Cancer;   Acute Myelogenous Leukemia
    Interventions:   Procedure: Biopsy;   Drug: ABIRATERONE;   Drug: ENZALUTAMIDE;   Drug: VENETOCLAX;   Drug: PALBOCICLIB;   Drug: All-trans Retinoic Acid;   Drug: BORTEZOMIB;   Drug: CABAZITAXEL;   Drug: OXALIPLATIN;   Drug: FLUOROURACIL;   Drug: FOLINIC ACID;   Drug: CARBOPLATIN;   Drug: PANOBINOSTAT;   Drug: VORINOSTAT;   Drug: PEMBROLIZUMAB;   Drug: BEVACIZUMAB;   Drug: IPILIMUMAB;   Drug: NIVOLUMAB;   Drug: EVEROLIMUS;   Drug: SIROLIMUS;   Drug: CELECOXIB;   Drug: OLAPARIB;   Drug: AFATINIB;   Drug: CABOZANTINIB;   Drug: SORAFENIB;   Drug: DASATINIB;   Drug: ERLOTINIB;   Drug: IDELALISIB;   Drug: IMATINIB;   Drug: LENVATINIB;   Drug: PERTUZUMAB;   Drug: PONATINIB;   Drug: RUXOLITINIB;   Drug: SUNITINIB;   Drug: TRAMETINIB;   Drug: VEMURAFENIB
    Sponsors:   OHSU Knight Cancer Institute;   Oregon Health and Science University
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma;   Philadelphia Chromosome Positive
    Interventions:   Drug: Cyclophosphamide;   Drug: Dasatinib;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    Interventions:   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Drug: Ruxolitinib Phosphate
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Lymphoma
    Interventions:   Drug: Prednisone;   Drug: Vincristine;   Drug: Daunorubicin;   Drug: Pegaspargase;   Drug: Erwinase®;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Mercaptopurine;   Drug: Dasatinib;   Drug: Methotrexate;   Drug: Blinatumomab;   Drug: Ruxolitinib;   Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Clofarabine;   Drug: Vorinostat;   Drug: Idarubicin;   Drug: Nelarabine
    Sponsors:   St. Jude Children's Research Hospital;   Bristol-Myers Squibb;   Incyte Corporation;   Shire
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Recurrent Adult Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia
    Interventions:   Biological: Blinatumomab;   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methotrexate Sodium;   Drug: Prednisone;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chronic Phase Chronic Myeloid Leukemia;   Chronic Myeloid Leukemia, Chronic Phase
    Interventions:   Drug: Ruxolitinib;   Drug: BCR-ABL Tyrosine Kinase Inhibitor (TKI)
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Jean Khoury Cure CML Consortium;   Incyte Corporation
    Not yet recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: Ceritinib;   Drug: dasatinib;   Drug: sorafenib;   Drug: vorinostat;   Drug: DFMO
    Sponsors:   Giselle Sholler;   Dell, Inc.;   Beat NB Cancer Foundation
    Recruiting

  • Conditions:   Urothelial Carcinoma;   Bladder Cancer;   Urinary Bladder Neoplasms
    Interventions:   Drug: 75 approved agents;   Other: COXEN
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chronic Myelogenous Leukemia;   Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
    Interventions:   Drug: ABL001;   Drug: ABL001 + Nilotinib;   Drug: ABL001+imatinib;   Drug: ABL001+dasatinib
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Acute Lymphoblastic Leukemia, Pediatric
    Interventions:   Drug: Pegaspargase;   Drug: Erwinia asparaginase;   Drug: Cyclophosphamide;   Drug: CYTARABINE;   Drug: DASATINIB;   Drug: DEXAMETHASONE;   Drug: Dexrazoxane;   Drug: Doxorubicin;   Drug: ETOPOSIDE;   Drug: HYDROCORTISONE;   Drug: LEUCOVORIN CALCIUM;   Drug: MERCAPTOPURINE;   Drug: METHOTREXATE;   Drug: NELARABINE;   Drug: Vincristine
    Sponsors:   Dana-Farber Cancer Institute;   Servier
    Recruiting

  • Conditions:   Acute Leukemia of Ambiguous Lineage;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory Childhood Acute Lymphoblastic Leukemia
    Interventions:   Other: Chemosensitivity Assay;   Other: Cytology Specimen Collection Procedure;   Genetic: Gene Expression Analysis;   Genetic: Genetic Variation Analysis;   Drug: In Vitro Sensitivity-Directed Chemotherapy
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting